Neogen Corporation (NEOG)
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NEOG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.30B
- Forward P/E
- 23.44
- EPS (TTM)
- -$0.26
- Dividend yield
- None
- 52-week range
- 5.60 – 14.26
- Day range
- 10.42 – 10.94
- Volume / Avg
- 3.04M / 3.53M
- Beta
- —
- Shares outstanding
- 218.31M
52-week range
NEOG stock today
Neogen (NEOG) closed at $10.55 on Nov 20, down 2.76% (-$0.30), versus the S&P 500's 3.70% decline. Shares are 26.0% below their 52-week high of $14.26, set on Sep 23, 2026 and 88.4% above the 52-week low of $5.60, in the middle of the past year's range. NEOG is up 50.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 84.4%.
Neogen has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neogen
Company profileNeogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Mikhael Nassif
- Headquarters
- Lansing, MI
- Employees
- 2,636
- IPO year
- 1989
- Website
- neogen.com
Financial highlights
Full financialsIn fiscal 2026, Neogen generated $870.4 million in revenue, down 2.7% from fiscal 2025, its first annual decline since 2025. Neogen reported a net loss of $7.9 million, compared with a loss of $1.09 billion a year earlier. Gross margin was 46.9% (down from 47.1%) and operating margin -2.5%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $870.40M | $894.70M | $924.20M | $822.45M | $527.16M |
| Growth | -2.72% | -3.19% | +12.37% | +56.01% | +12.53% |
| Net income | $-7.90M | $-1.09B | $-9.40M | $-22.87M | $48.31M |
| EPS (diluted) | $-0.04 | $-5.03 | $-0.04 | $-0.12 | $0.45 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$14.00+32.70%
- Strong buy 2
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Aug/2026)
- Oct 6, 2026
- EPS actual vs est.
- $-0.05 vs $0.04
- Surprise
- -225.00%
NEOG news
All NEOG news- Why is Neogen stock gaining today?Investing.com
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOGPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOGPR Newswire
- Neogen Corporation Expects Genomics Sale Regulatory Review to Conclude in early 2027NasdaqNEOG, BRK.A
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOGPR Newswire
- Neogen Corporation Shareholders Approve Amended and Restated Omnibus Incentive PlanNasdaqNEOG, HEI.A
- Tuesday 10/13 Insider Buying Report: IMSR, NEOGNasdaqIMSR, NEOG
- Neogen (NEOG) Q1 Earnings and Revenues Beat EstimatesNasdaqNEOG, BIO
Neogen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLDXCelldex Therapeutics Inc. | 27.42 | -1.93% | $2.15B | vs NEOG |
| NTLAIntellia Therapeutics Inc. | 10.00 | +5.04% | $1.40B | vs NEOG |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs NEOG |
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs NEOG |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs NEOG |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs NEOG |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs NEOG |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs NEOG |
Indexes, lists and sector
Neogen stock FAQ
What is Neogen's stock price today?
NEOG last traded at $10.55 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.
Does Neogen pay a dividend?
No. Neogen does not currently pay a regular cash dividend.
Who is Neogen's CEO?
Mr. Mikhael Nassif is the chief executive officer of Neogen Corporation, which has about 2,636 employees.
Has NEOG ever split its stock?
Yes. The most recent NEOG stock split was a 2-for-1 split on Jun 7, 2021, one of 6 splits on record.
What is the NEOG 52-week high?
The 52-week high for NEOG is $14.26 and the 52-week low is $5.60. The stock is currently 26.0% below its high.